Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

55 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The impact of tumour histology and recursive partitioning analysis classification on the prognosis of patients treated with whole-brain hypofractionated radiotherapy for brain metastases: analysis of 382 patients.
Buglione M, Bandera L, Grisanti S, Pasinetti N, Borghetti P, Barbera F, Triggiani L, Costa L, Shehi B, Bonetti B, Magrini S. Buglione M, et al. Among authors: pasinetti n. Radiol Med. 2012 Feb;117(1):133-47. doi: 10.1007/s11547-011-0738-x. Epub 2011 Oct 21. Radiol Med. 2012. PMID: 22020431 English, Italian.
The treatment of patients with 1-3 brain metastases: is there a place for whole brain radiotherapy alone, yet? A retrospective analysis.
Buglione M, Pedretti S, Gipponi S, Buttolo L, Panciani P, Poliani PL, Liserre R, Borghetti P, Pegurri L, Costa L, Triggiani L, Pasinetti N, Ghirardelli P, Pandini S, Padovani A, Magrini SM; Neuro-Oncology Group, Spedali Civili Hospital and Brescia University. Buglione M, et al. Among authors: pasinetti n. Radiol Med. 2015 Dec;120(12):1146-52. doi: 10.1007/s11547-015-0542-0. Epub 2015 Apr 28. Radiol Med. 2015. PMID: 25917339
Radiotherapy for adult medulloblastoma: Long term result from a single institution. A review of prognostic factors and why we do need a multi-institutional cooperative program.
Buglione M, Ghirardelli P, Triggiani L, Pedretti S, Pasinetti N, De Bari B, Tonoli S, Borghetti P, Spiazzi L, Magrini SM. Buglione M, et al. Among authors: pasinetti n. Rep Pract Oncol Radiother. 2015 Jul-Aug;20(4):284-91. doi: 10.1016/j.rpor.2015.03.003. Epub 2015 Apr 8. Rep Pract Oncol Radiother. 2015. PMID: 26109916 Free PMC article.
Cetuximab and Radiotherapy Versus Cisplatin and Radiotherapy for Locally Advanced Head and Neck Cancer: A Randomized Phase II Trial.
Magrini SM, Buglione M, Corvò R, Pirtoli L, Paiar F, Ponticelli P, Petrucci A, Bacigalupo A, Crociani M, Lastrucci L, Vecchio S, Bonomo P, Pasinetti N, Triggiani L, Cavagnini R, Costa L, Tonoli S, Maddalo M, Grisanti S. Magrini SM, et al. Among authors: pasinetti n. J Clin Oncol. 2016 Feb 10;34(5):427-35. doi: 10.1200/JCO.2015.63.1671. Epub 2015 Dec 7. J Clin Oncol. 2016. PMID: 26644536 Clinical Trial.
Resected pN1 non-small cell lung cancer: recurrence patterns and nodal risk factors may suggest selection criteria for post-operative radiotherapy.
Borghetti P, Barbera F, Bonù ML, Trevisan F, Ciccarelli S, Vitali P, Maddalo M, Triggiani L, Pasinetti N, Pedretti S, Bonetti B, Pariscenti G, Tironi A, Caprioli A, Buglione M, Magrini SM. Borghetti P, et al. Among authors: pasinetti n. Radiol Med. 2016 Sep;121(9):696-703. doi: 10.1007/s11547-016-0648-z. Epub 2016 May 26. Radiol Med. 2016. PMID: 27230669
Subgroup Analysis According to Human Papillomavirus Status and Tumor Site of a Randomized Phase II Trial Comparing Cetuximab and Cisplatin Combined With Radiation Therapy for Locally Advanced Head and Neck Cancer.
Buglione M, Maddalo M, Corvò R, Pirtoli L, Paiar F, Lastrucci L, Stefanacci M, Belgioia L, Crociani M, Vecchio S, Bonomo P, Bertocci S, Borghetti P, Pasinetti N, Triggiani L, Costa L, Tonoli S, Grisanti S, Magrini SM. Buglione M, et al. Among authors: pasinetti n. Int J Radiat Oncol Biol Phys. 2017 Mar 1;97(3):462-472. doi: 10.1016/j.ijrobp.2016.10.011. Epub 2016 Oct 20. Int J Radiat Oncol Biol Phys. 2017. PMID: 27986347 Clinical Trial.
Efficacy of stereotactic body radiotherapy in oligorecurrent and in oligoprogressive prostate cancer: new evidence from a multicentric study.
Triggiani L, Alongi F, Buglione M, Detti B, Santoni R, Bruni A, Maranzano E, Lohr F, D'Angelillo R, Magli A, Bonetta A, Mazzola R, Pasinetti N, Francolini G, Ingrosso G, Trippa F, Fersino S, Borghetti P, Ghirardelli P, Magrini SM. Triggiani L, et al. Among authors: pasinetti n. Br J Cancer. 2017 Jun 6;116(12):1520-1525. doi: 10.1038/bjc.2017.103. Epub 2017 Apr 27. Br J Cancer. 2017. PMID: 28449007 Free PMC article.
Salvage Low Dose Rate Brachytherapy For Recurrent Prostate Cancer After External Beam Radiotherapy: Results From A Single Institution With Focus On Toxicity And Functional Outcomes.
Barbera F, Triggiani L, Buglione M, Ghirardelli P, Vitali P, Caraffini B, Borghetti P, Greco D, Bardoscia L, Pasinetti N, Costa L, Maddalo M, Ghedi B, La Face B, Magrini SM. Barbera F, et al. Among authors: pasinetti n. Clin Med Insights Oncol. 2017 Nov 7;11:1179554917738765. doi: 10.1177/1179554917738765. eCollection 2017. Clin Med Insights Oncol. 2017. PMID: 29151782 Free PMC article.
55 results